SOURCE: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals, Inc.

September 14, 2010 07:30 ET

Sunesis to Present at the UBS Global Life Sciences Conference

SOUTH SAN FRANCISCO, CA--(Marketwire - September 14, 2010) -  Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at the UBS Global Life Sciences Conference on Tuesday, September 21, 2010 at 1:30 P.M. Eastern Time at the Grand Hyatt New York.

A live webcast of this presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Contact Information

  • Investor and Media Inquiries:
    David Pitts
    Argot Partners
    212-600-1902

    Eric Bjerkholt
    Sunesis Pharmaceuticals Inc.
    650-266-3717